Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin,Yanping Sun,Xiao Liang,Xinyu Gu,Jiangtao Ning,Yingchun Xu,Shuqing Chen,Liqiang Pan
DOI: https://doi.org/10.1038/s41392-021-00868-x
IF: 39.3
2022-02-07
Signal Transduction and Targeted Therapy
Abstract:Abstract Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells. The successful application of IgG monoclonal antibodies has inspired the development of various types of therapeutic antibodies, such as antibody fragments, bispecific antibodies, and antibody derivatives (e.g., antibody–drug conjugates and immunocytokines). The miniaturization and multifunctionalization of antibodies are flexible and viable strategies for diagnosing or treating malignant tumors in a complex tumor environment. In this review, we summarize antibodies of various molecular types, antibody applications in cancer therapy, and details of clinical study advances. We also discuss the rationale and mechanism of action of various antibody formats, including antibody–drug conjugates, antibody–oligonucleotide conjugates, bispecific/multispecific antibodies, immunocytokines, antibody fragments, and scaffold proteins. With advances in modern biotechnology, well-designed novel antibodies are finally paving the way for successful treatments of various cancers, including precise tumor immunotherapy, in the clinic.
biochemistry & molecular biology,cell biology